HETEROBIFUNCTIONAL ANTIBODIES IN TUMOR TARGETING

T细胞、NK细胞和巨噬细胞的抗肿瘤活性可以 通过淋巴因子和细胞因子、单克隆抗体 抗肿瘤抗原的单克隆抗体（Mab），以及Mab和 效应细胞激活剂。 具有双重特异性的异源抗体 通过化学交联抗人类的单克隆抗体， T细胞CD 3抗原与识别表面抗原的抗体 结肠和卵巢肿瘤。 利用正常人外周血 淋巴细胞，结果表明，这些异源抗体，并在一些 例，单体抗肿瘤单抗，增强了对 培养的肿瘤细胞。 此外，异源抗体导向的 细胞毒性通过效应细胞活化而增强， IL-2或抗CD 3单克隆抗体。 因此，异源抗体可以提供一种新的 用于靶向细胞毒性免疫细胞以 肿瘤的

The anti-tumor activity of T-cells, NK cells, and macrophages can be augmented by lymphokines and cytokines, monoclonal antibodies (Mabs) against tumor antigens, and combinations of Mabs and effector cell activators. Heteroantibodies with dual specificity were constructed by chemically cross-linking Mab against the human T-cell CD3 antigen with antibodies recognizing surface antigens on colon and ovarian tumors. Utilizing normal human peripheral blood lymphocytes, it was shown that these heteroantibodies, and in some cases, monomeric anti-tumor Mab, potentiated the killing of cultured tumor cells. In addition, heteroantibody-directed cytotoxicity was enhanced by effector cell activation with either IL-2 or anti-CD3 Mab. Thus, heteroantibodies may provide a new immunotherapeutic strategy for targeting cytotoxic immune cells to tumors.